论文部分内容阅读
目的探讨阿托伐他汀、缬沙坦、降纤酶联合治疗慢性肺源性心脏病急性加重期的疗效。方法将96例肺心病急性加重期患者随机分为治疗组56例,对照组40例,对照组采用常规治疗,治疗组在常规治疗的基础上加阿托伐他汀、缬沙坦、降纤酶治疗2周后分别测心肺功能、血流变并观察疗效。结果治疗组LVEF、FEV1/FVC较治疗前均明显改善、差异有统计学意义(P<0.05),与对照组治疗后比较差异也有统计学意义(P<0.05)。对照组临床总有效率为65.0%(26/40),治疗组临床总有效率为91.1%(51/56),两组总有效率比较差异有统计学意义(P<0.05)。结论肺病急性加重期患者在常规治疗基础上加阿托伐他汀、缬沙坦、降纤酶对改善心肺功能血流变学和临床症状具有较好作用。
Objective To investigate the effect of combination of atorvastatin, valsartan and defibrase in the treatment of acute exacerbation of chronic cor pulmonale. Methods Ninety-six patients with acute exacerbation of pulmonary heart disease were randomly divided into treatment group (56 cases) and control group (40 cases). The control group received routine treatment. The treatment group received atorvastatin, valsartan, defibrase After 2 weeks of treatment, respectively, measured heart and lung function, blood rheology and observe the effect. Results The LVEF and FEV1 / FVC in the treatment group were significantly improved compared with those before treatment (P <0.05), and there was also a significant difference between the two groups after treatment (P <0.05). The total effective rate in the control group was 65.0% (26/40). The total effective rate in the treatment group was 91.1% (51/56). The total effective rate in the two groups was statistically significant (P <0.05). Conclusion In patients with acute exacerbation of lung disease, atorvastatin, valsartan and defibrase are effective in improving the cardiopulmonary dysfunction and clinical symptoms on the basis of routine treatment.